Abstract
The World Health Organization revised NTD Roadmap and its newly launched Guidelines target elimination of schistosomiasis as a public health problem in all endemic areas by 2030. Key to meeting this goal is elucidating how selective pressures imposed by interventions shape parasite populations. Our aim was to identify any differential impact of a unique cluster-randomized tri-armed elimination intervention (biannual mass drug administration (MDA) applied alone or in association with either mollusciciding (snail control) or behavioural change interventions) across two Zanzibarian islands (Pemba and Unguja) on the population genetic composition of Schistosoma haematobium over space and time. Fifteen microsatellite loci were used to analyse individual miracidia collected from infected individuals across islands and intervention arms at the start (2012 baseline: 1,529 miracidia from 181 children; 303 from 43 adults; age-range 6-75, mean 12.7 years) and at year 5 (2016: 1,500 miracidia from 147 children; 214 from 25 adults; age-range 9-46, mean 12.4 years). Measures of genetic diversity included allelic richness (Ar), inbreeding coefficient (FST), parentage analysis, estimated worm burden, worm fecundity, and genetic sub-structuring. There was little evidence of differential selective pressures on population genetic diversity, outbreeding or estimated worm burdens by treatment arm, with only the MDA+snail control arm within Unguja showing a (non-significant) trend towards reduced diversity over time. The greatest differences overall, most notably in terms of parasite fecundity (mean number of eggs per adult female worm) and genetic sub-structuring, were observed between the islands, consistent with Pemba’s persistently higher mean infection intensities compared to neighbouring Unguja, and within islands in terms of persistent infection hotspots (across three definitions). These findings highlight the important contribution of population genetic analyses to elucidate extensive genetic diversity and biological drivers, including potential gene-environmental factors, that may override short term selective pressures imposed by differential disease control strategies.
Author Summary Schistosomiasis is a parasitic disease caused by infection with blood flukes, which leads to acute and chronic pathology in millions of infected individuals, particularly those within the poorest tropical and subtropical regions. In 2012, the World Health Organization (WHO) set the ambitious goals to achieve Elimination of Schistosomiasis as a Public Health Problem (i.e., EPHP, prevalence of heavy infection intensity less than 1% in all sentinel sites) and complete Interruption of Transmission (i.e., IoT reduction of incidence of infection to zero) in selected African regions by 2025. More recently, the revised WHO Neglected Tropical Diseases (NTD)-Roadmap and Revised Schistosomiasis Control and Elimination Guidelines aim to achieve EPHP in all regions by 2030. Here we analysed population genetic data associated with a unique 5-year cluster-randomized trial across Zanzibar (Pemba and Unguja islands) which aimed to assess the impact of contrasting interventions to achieve urogenital schistosomiasis elimination. Whilst, consistent with the main trial study, no significant differential impact of interventions was detected in terms of infection epidemilogy, our data suggested that the greatest impact on genetic diversity was within the mass drug administration plus concurrent mollusciding arm. Moreover, our analyses revealed significant differences in both the genetic sub-structuring and notably the fecundity of parasites between Pemba and Unguja islands, and within Pemba island in relation to persistent hotspots, potentially indicative of genetic and biological factors driving persistence. These findings highlight the important contribution of population genetic analyses to reveal high levels of genetic diversity, biological drivers and potential gene-environmental interactions in determining infection dynamics and persistence, all of which present additional challenges for successful control.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The cluster randomized trial is registered at the International Standard Randomised Controlled Trial, Register Number (ISRCTN48837681).
Funding Statement
This study received financial support from the Bill and Melinda Gates Foundation (BMGF), via University of Georgia Research Foundation, Inc (UGARF) for the Schistosomiasis Consortium for Operational Research Evaluation (SCORE) projects (Population Genetics Grant Refs RR374-053/5054146 & RR374-053/4785426 PIs JPW & DR) https://score.uga.edu/about/ The funders had no role in the population genetics study design, data collection and analysis, decision to publish or preparation of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the cluster randomized trial was obtained from the Zanzibar Medical Research Ethics Committee (ZAMREC 0003/Sept/011), the ?Ethikkomission beiber Basel? (EKBB) in Switzerland (reference no. 236/11), and the Institutional Review Board of the University of Georgia (project no. 2012-10138-0). The cluster randomized trial is registered at the International Standard Randomised Controlled Trial, Register Number (ISRCTN48837681). Further approval for the population genetic analyses was obtained from the St Mary?s Hospital Local Ethics Research Committee, R&D office, part of the Imperial College, London Research Ethics Committee (ICREC (EC NO: 03.36. R&D No: 03/SB/033E)).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All remaining miracidial samples on Whatman FTA cards and associated DNA extractions have been bio-banked within the Schistosomiasis Collection at the Natural History Museum (SCAN: https://scan.myspecies.info/). The data that support the epidemiological findings of this study are openly available in ClinEpiDB. The dataset ?Study: SCORE Zanzibar S. haematobium Cluster Randomized Trial? can be found at https://clinepidb.org/ce/app/record/dataset/DS_eddb4757ba. Microsatellite data associated with the representative schistosome samples are available in the supplementary material associated with this publication.
